N/A N=20 Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study
Lynch Syndrome
Primary: Acceptability of Workbook Assessed Through Likert Score Scale — 10; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=340 Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
N/A N=12 Studies in Patients With Low Anterior Resection Syndrome (LARS)
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
Phase 2 N=33 Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Phase 2 N=11 TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Colorectal Cancer
Primary: Overall Response Rate — 0; 0; 5; 4 Participants
Phase 2 N=47 Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Familial Adenomatous Polyposis
Primary: 13-HODE Colonic Tissue Levels — 14.56; 18.83; 23.02; 20.03 ng/mg tissue protein
N/A N=505 Impact of Family History and Decision Support on High-risk Cancer Screening
Colorectal Cancer
Primary: Number of Patients With Provider Referral for Risk-appropriate Colorectal Cancer Screening — 219; 232 Participants — p=0.16
N/A N=230 Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)
Non Small-cell Lung Cancer
Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Phase 3 N=335 Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
Metastatic Colorectal Cancer
Primary: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) — 3.7…
N/A N=2,004 Study of Colorectal Cancer Screening Options
Colon Cancer
Primary: Assess Colorectal Cancer Screening Completion — 305; 130 Participants
Phase 2 N=36 A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Overall Response Rate — 0 participants
Phase 2 N=195 Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
Gastric Cancer · Gastric Neoplasms · Gastric Adenocarcinoma
Primary: Proportion of Participants With Improved Sensitivity for Detection of Early-stage Gastric Cancer in CDH1 Germline Mutation Carriers Compared to the Cambridge Method — 1…
Phase 2 N=135 Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Rectal Carcinoma
Primary: Rate of Tumor Downstaging Compared With Historical Controls. — 64.4; 64.5 percentage of participants
Phase 2 N=100 Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
Colon Cancer
Primary: Progression Free Survival — 38; 34; 6; 3 Participants
N/A N=239 Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer
Colorectal Cancer · Hereditary Non-polyposis Colon Cancer
Primary: Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing — 4.07; 4.17 units on a scale
N/A N=14,263 Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
Colorectal Cancer · Advanced Adenocarcinoma · Serrated Polyp
Primary: ColoSense Sensitivity for Colorectal Cancer (CRC) — 25; 2 Participants
Phase 2 N=46 Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Attenuated Familial Adenomatous Polyposis · Familial Adenomatous Polyposis
Primary: Mean Percent Change in Duodenal Polyp Burden — -29.6 percent change in Duodenal Polyp Burden
N/A N=8 Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention
Colorectal Cancer
Primary: Percent of Patients Receiving GI Consult for FOBT+ Results — 39; 47; 64; 51 percent patients receiving GI consult
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 2 N=16 Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
Phase 1 N=23 Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Phase 2 N=199 LY353381 in Preventing Breast Cancer in Women With Hyperplasia
Breast Cancer
Primary: Change in Masood Score — -1.1; -0.8 units on a scale
N/A N=115,484 Early Detection of GEnetic Risk (EDGE)
Genetic Predisposition
Primary: Rates of Screening — 9892; 3813 Participants — p=0.0074
N/A N=250 Precision-Based Magnesium Trial
Colorectal Cancer
Primary: TRPM7 Expression Level in Colorectal Mucosa by Mg Treatment Compared With Placebo — 0.03; 0.08; -0.09; -0.11 log (arbitrary units) — p=>0.05
N/A N=11 Familial Hyperlipidemia Family Registry
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants
Phase 2 N=124 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Colorectal Carcinoma
Primary: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor — 32.8; 34.9 Percentage of participants
Phase 2 N=6 A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
HER2 Amplified Breast Cancer
Primary: Changes in Colon Pathology — 2; 2 participants
Phase 2 N=92 A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Adenomatous Polyposis Coli
Primary: Change in Duodenal Polyp Burden From Baseline to 6 Months — -8.5; 8.0 mm — p=<0.001
Phase 2 N=44 Curcumin in Treating Patients With Familial Adenomatous Polyposis
Familial Adenomatous Polyposis
Primary: Polyp Number — 22.6; 18.6 polyps — p=0.58